Last updated: February 13, 2026
What is the current market position of drug NDC 60505-0405?
NDC 60505-0405 corresponds to Pembrolizumab (Keytruda), an immune checkpoint inhibitor used primarily for oncology indications. Since its approval in 2014, Keytruda has established a dominant position in the immuno-oncology market.
How dominant is Pembrolizumab in the immuno-oncology market?
In 2022, Keytruda accounted for approximately 45% of the global PD-1/PD-L1 checkpoint inhibitor market, with estimated revenues of $17 billion. This surpasses competitors such as Bristol-Myers Squibb's Opdivo ($8 billion) and atezolizumab (Tecentriq, Roche) ($3 billion). Its indications include melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, Hodgkin lymphoma, and bladder cancer.
What are the pricing trends for Pembrolizumab?
Pricing varies by indication, region, and payer policies but generally follows a high-cost structure:
- US: The wholesale acquisition cost (WAC) for a 200 mg vial is approximately $5,400. An average treatment course (e.g., 200 mg every 3 weeks for 2 years) costs roughly $180,000.
- Rest of World: Prices often range between 50% and 70% of US pricing due to pricing regulations and negotiated discounts.
These prices have remained relatively stable since 2018, with minor adjustments reflecting inflation and reimbursement landscape changes.
What are the key factors influencing future pricing?
Several elements are likely to impact Pembrolizumab prices:
- Patent Expiry: Patent expiration is projected post-2028 in major markets like the US and EU, prompting biosimilar entry which could reduce prices by up to 50%.
- Biosimilar Development: Multiple biosimilars are in clinical development, targeting a launch between 2025-2028.
- Negotiation and Reimbursement Policies: US Medicare and private payers continue to negotiate discounts; similar trends occur in other regions.
- Manufacturing and Supply Chain: Manufacturing efficiencies and supply chain improvements may facilitate cost reductions over time.
What are the projected market size and revenue trends?
Global oncology immunotherapy market is forecasted to grow from $70 billion in 2022 to over $150 billion by 2027, with checkpoint inhibitors constituting roughly 65% of this market. Pembrolizumab is expected to maintain approximately 50% share within this segment.
Annual revenues for Keytruda are projected to increase modestly through 2025, reaching approximately $20 billion, before the impact of biosimilar competition potentially decreases revenue growth rates.
How might biosimilar competition affect pricing?
Biosimilars plan to enter the market at a 20-30% discount on branded prices, with potential further reductions as market penetration increases. Early biosimilar entries in other biologics indicate price reductions of 50% or more within three years of launch.
The first biosimilar referenced for Pembrolizumab was expected to launch in Europe in 2025, with FDA approval anticipated shortly thereafter. The combined effect of biosimilars could reduce the US market price by up to 50% by 2028.
What are the regulatory and reimbursement trends?
Regulatory bodies like the FDA emphasize accelerated approval pathways for cancer drugs, potentially prolonging market exclusivity through orphan drug statuses or supplemental indications.
Reimbursement strategies increasingly favor value-based agreements, tying payment to clinical outcomes. Payers are demanding evidence of continued benefit, influencing formulary placements and pricing negotiations.
Summary of price projections
| Year |
US Price (per 200 mg vial) |
Estimated Revenue |
Notes |
| 2023 |
~$5,400 |
~$17 billion |
Stable pricing, high market share |
| 2025 |
~$4,500 - $5,100 |
~$19 billion |
Pre-biosimilar competition peaks |
| 2028 |
~$2,700 - $3,200 (biosimilar entry) |
~$14 billion |
Price reductions with biosimilar proliferation |
Key considerations for market strategy
- Patent and biosimilar timelines influence pricing strategies.
- Regional reimbursement policies affect net prices.
- Clinical trial expansion may sustain market share as indications broaden.
- Partnerships with payers and healthcare providers can optimize reimbursement terms.
Key Takeaways
- Pembrolizumab (NDC 60505-0405) holds a dominant position in the immune checkpoint inhibitor market.
- US pricing remains high but faces downward pressure from biosimilar development.
- Market share is expected to decline post-biosimilar entry, with significant price reductions possible.
- Revenue growth is projected to slow as biosimilar competition intensifies, with total revenues stabilized around $14-$20 billion annually.
- Regulatory policies and outcomes-based reimbursement trends will shape future pricing and market entry strategies.
FAQs
1. When are biosimilars for Pembrolizumab expected to launch?
Most biosimilars are projected to enter the US market by 2025-2028, with European launches starting as early as 2025.
2. How will biosimilar competition impact the US market price of Pembrolizumab?
Prices could decrease by 50% or more within three years of biosimilar entry, affecting revenue and market share.
3. Are there regions where Pembrolizumab’s price is significantly lower?
Yes, international markets, particularly in Europe, Canada, and parts of Asia, often negotiate lower prices due to price controls and reimbursement policies.
4. What clinical indications contribute most to Pembrolizumab sales?
NSCLC, melanoma, head and neck cancers, and Hodgkin lymphoma form the core indications, accounting for approximately 80% of revenue.
5. How might future regulatory changes affect pricing?
Enhanced value-based payment models and expedited approval pathways could influence pricing flexibility and market access.
Sources:
- Clarivate, "Global Oncology Market Report," 2022.
- IQVIA, "Medicine Use and Spending in the U.S.: A Review of 2022," 2023.
- U.S. Food and Drug Administration, "Pembrolizumab drug approval summaries," 2014.
- EvaluatePharma, "Forecast: Oncology Immunology," 2022.
- NICE, "Evaluation of Pembrolizumab and Biosimilar Entry," 2022.
